NASDAQ$NAGE
Niagen Bioscience Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Niagen Bioscience reported Q1 2026 net sales of $31.5M and net income of $6.3M, or $0.07 diluted EPS.
For the quarter ended March 31, 2026, Niagen (NAGE, formerly ChromaDex) posted net sales of $31.5 million versus $30.5 million a year ago, led by Tru Niagen ingredient and consumer products. Net income was $6.3 million, or $0.07 per diluted share, compared with $5.1 million and $0.06 in Q1 2025.
- Net sales $31.5M (+3% YoY).
- Net income $6.3M; diluted EPS $0.07.
- Analytical standards business sold; transition services revenue minimal.
- NAD+ precursor R&D continues without product revenue yet.
Headline financials
Revenue & EPS history
Niagen Bioscience Inc · Revenue · Quarterly
$31.5M
Forward guidance
Consumer adoption of Niagen, international expansion, and pharma partnerships frame growth; no formal EPS guide in 10-Q.
Tailwinds
- Profitable growth on ingredient demand.
- Margin stability in core segments.
Headwinds
- Modest top-line growth rate.
- Concentration in Niagen brand acceptance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+0.5%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+7.3%
Q2 2022
Best reaction
-6.7%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.1% | -17.4% | -28.6% | |
| Q4 2025 | +3.2% | +5.7% | -11.3% | |
| Q3 2025 | -3.9% | -5.4% | -7.3% | |
| Q1 2025 | -3.2% | +7.6% | +48.3% | |
| Q3 2024 | -2.5% | +70.7% | +115.6% | |
| Q2 2024 | -6.7% | +0.0% | +18.1% | |
| Q1 2024 | +2.1% | -9.9% | -14.7% | |
| Q3 2023 | +4.6% | -11.1% | -12.4% | |
| Q2 2023 | -0.6% | -4.2% | -7.2% | |
| Q1 2023 | +5.8% | +9.4% | +14.4% | |
| Q3 2022 | +1.8% | +31.7% | +6.7% | |
| Q2 2022 | +7.3% | -8.3% | -25.5% | |
| Q1 2022 | +0.6% | +12.3% | +29.4% | |
| Q3 2021 | +2.2% | +0.3% | -32.1% | |
| Q2 2021 | -2.1% | -2.0% | -9.2% | |
| Q1 2021 | -3.9% | -20.7% | +0.1% | |
| Q3 2020 | +1.5% | +2.1% | +3.8% | |
| Q2 2020 | -4.3% | -7.2% | -12.1% | |
| Q1 2020 | +3.9% | +5.4% | -7.6% | |
| Q3 2019 | -0.7% | +11.6% | +38.2% | |
| Q2 2019 | -2.2% | -7.6% | -9.4% | |
| Q1 2019 | +1.9% | +0.4% | -12.0% | |
| Q3 2018 | +6.0% | -1.1% | -9.2% | |
| Q2 2018 | +2.3% | +0.0% | -18.3% | |
| Q1 2018 | -2.9% | -5.2% | -1.0% | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro